Treatment efficacy obtained by injection versus continuous infusion has also been investigated for the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, of which the injectable version is approved as treatment for patients with inadequately controlled type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.